US Food and Drug Administration (FDA) approves Glenmark's Fluticasone Propionate Nasal Spray

Key facts

• US Food and Drug Administration (FDA) approved Glenmark Pharmaceuticals' Fluticasone Propionate Nasal Spray on August 20, 2026.
• Glenmark's Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Haleon US Holdings LLC's Flonase Nasal Spray.
• The approved product will be distributed in the US by Glenmark Pharmaceuticals Inc, USA.
• The Flonase Nasal Spray market, including brand and all therapeutic equivalents, recorded annual sales of approximately $295.2 million in the 12 months ending June 2026, as per IQVIA sales data.
• Glenmark's consolidated profit after tax in Q1FY27 rose to ₹482.83 crore from ₹46.97 crore in the corresponding quarter of the previous fiscal.
• Glenmark's consolidated total revenue from operations in Q1FY27 stood at ₹4,018.48 crore compared with ₹3,264.44 crore in the year-ago period.